p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis

Blood

Volumn 91, Issue 11, 1998, Pages 4342-4349

  Cordone, Iole ^a   Masi, Serena ^b   Mauro, Francesca Romana ^b   Soddu, Silvia ^b   Morsilli, Ornella ^b   Valentini, Tiziana ^b   Vegna, Maria Luce ^b   Guglielmi, Cesare ^b   Mancini, Francesca ^b   Giuliacci, Sonia ^b   Sacchi, Ada ^b   Mandelli, Franco ^b   Foa, Robert ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 17744410949     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4342.411k39_4342_4349     Document Type: Article

References (56)

1. Keating MJ: Chemotherapy of chronic lymphocytic leukemia, in Cheson BD (ed): Chronic Lymphocytic Leukemia. Scientific Advances and Clinical Developments. New York. NY, Marcel Dekker, 1993, p 297
2. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052, 1995
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453, 1991
4. Lane DP: p53 guardian of the genome. Nature 358:15, 1992
5. Hollstein M, Sidransky D, Vogelstein D, Harris CC: p53 mutations in human cancers. Science 253:49, 1991
6. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RSK. Dalla Favera R: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289, 1993
7. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
8. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892, 1995
9. Greiner T, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson J, Weisenburger D: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302, 1996
10. Zoldan MC, Inghirami G, Masuda Y, Vandekerckhove F, Raphael B, Amorosi E, Hymes K, Frizzera G: Large-cell variants of mantle cell lymphoma: Cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 93:475, 1996
11. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601, 1997
12. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
13. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefevre MH, Bauters F, Berger R, Kerckaert P: Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 6:246, 1992
14. El Rouby, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent to MDR1/MDR3 gene expression. Blood 82:3452, 1993
15. Gandini D, Aguiari GL, Cuneo A, Piva R, Castoldi GL, Del Senno L: Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia. Br J Haematol 88:881, 1994
16. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle P, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580, 1995
17. Cuneo A, De Angeli C, Roberti MG, Piva N, Bigoni R, Gandini D, Rigolin GM, Moretti S, Cavazzini P, Del Senno L, Castoldi G: Richter's syndrome in a case of atypical chronic lymphocytic leukaemia with the t(11;14)(q13;q32): Role for a p53 exon 7 gene mutation. Br J Haematol 92:375, 1996
18. Cano I, Martinez J, Quevedo E, Pinilla J, Martin-Recio A, Rodriguez A, Castaneda A, Lopez R, Perez-Pino T, Hernandez-Navarro F: Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: Association with morphology and resistance to conventional chemotherapy. Cancer Genet Cytogenet 90:118, 1996
19. Lens D, De Schouwer PJJC, Hamoudi RA, Abdul-Rauf M, Farahat N, Matutes E, Crook T, Dyer MJS, Catovsky D: p53 abnormalities in B-cell prolymphocytic leukemia. Blood 89:2015, 1997
20. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595, 1990
21. Lepelley P, Preudhomme C, Vanrumbeke M. Quesnel B, Cosson A, Fenaux P: Detection of p53 mutations in hematological malignancies: Comparison between immunocytochemistry and DNA analysis. Leukemia 8:1342, 1994
22. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, SanchezVerde L, Martinez JC, Orradre JL, Garcia P, Lopez C, Martinez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 mutations. Blood 82:3151, 1993
23. Cesarman E, Inghirami G, Chadbum A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutation in anaplastic large cell lymphoma. Am J Pathol 143:845, 1993
24. De Re V, Carbone A, De Vita S, Gloghini A, Maestro R, Gasparotto D, Vukosavljevic T, Boiocchi M: p53 protein overexpression and p53 gene abnormalities in HIV-1-related non-Hodgkin's lymphomas. Int J Cancer 56:662, 1994
25. Matsushima AY, Cesarman E, Knowles DM: Mutations are not detected outside p53 exons 5 to 9 in lymphoid tumours. Lab Invest 70:115A, 1994
26. Matsushima AY, Cesarman E, Chadburn A, Knowles DM: Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144:573, 1994
27. Piris MA, Villuendas R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo MS, Martinez P: p53 expression in non-Hodgkin's lymphomas: A marker of p53 inactivation? Leuk Lymphoma 17:35, 1995
28. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351, 1996
29. Aguilar-Santelises M, Magnusson KP, Wiman KG, Mellstedt H, Jondal M: Progressive B-cell chronic lymphocytic leukemia frequently exhibits aberrant p53 expression, Int J Cancer 58:474, 1994
30. Reich NC, Levine AJ: Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308:199, 1984
31. Danova M, Giordano M, Mazzini G, Riccardi A: Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk Res 14:417, 1990
32. Korkolopoulou P, Oates J, Kittas C, Crocker J: p53. c-myc, p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. J Clin Pathol 47:9, 1994
33. Cordone I, Matutes E, Catovsky D: Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: Correlation with disease activity. Leukemia 6:902, 1992
34. International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 110:236, 1989
35. Melo JV, Catovsky D, Galton DAG: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 63:377, 1986
36. French Cooperative Group on chronic lymphocytic leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of a randomized clinical trial on 612 patients. Blood 75:1414, 1990
37. Catovsky D, Fooks J, Richards S: Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. Br J Haematol 72:141, 1989
38. Cheson BD, Bennet JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152, 1988
39. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: Prognostic value of complementery DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173, 1996
40. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M: Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69:114, 1996
41. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P: p53 protein expression in lymphomas and reactive lymphoid tissues. J Pathol 166:235, 1992
42. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler HP: Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 141:1343, 1992
43. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY: Immunohistochemical detection of p53 and bc12 proteins in non-Hodgkin's lymphomas. Histopathology 22:39, 1993
44. Inghirami G, Macri L, Cesarman E, Chadburn A, Zhong J, Knowles DM: Molecular characterization of CD30+ anaplastic large-cell lymphoma: High frequency of c-myc proto-oncogene activation. Blood 83:3581, 1994
45. lmamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994
46. Wattel E, Preudhomme C, Hecquet B, Varumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
47. Sidansky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846, 1992
48. Wada H, Asada M, Nakazawa S, Itoh H, Kobayashi Y, Inoue T, Fukumoro K, Han LC, Sugita K, Hanada R, Akuta N, Kobayashi N, Mizutani S: Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8:53, 1994
49. Garcia-Marco JA, Price CM, Ellis J, Motey M, Matutes M, Lens D, Colman S, Catovsky D: Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 10:1705, 1996
50. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855, 1994
51. Scott N, Sgar P, Stewart J, Blair GE, Dixon MF, Quirke P: p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 63:317, 1991
52. Thor AD, Moore DH, Edgerton S, Kawasaki E, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L, Mayall BH, Smith H: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845, 1992
53. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J. Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53, 1993
54. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859, 1992
55. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828, 1992
56. Visakorpi T, Kallionemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883, 1992